FGAM
KYMR icon

Financial Gravity Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Financial Gravity Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$67 – 1636
2024
Q1 		$67 Buy
+2
New +$72 ﹤0.01% 1010
2023
Q4 		– Hold
0
– – – 1230

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Financial Gravity Asset Management's KYMR Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 2 shares — an estimated $67 sold.

Financial Gravity Asset Management first reported a position in KYMR in Q1 2024 and held it in 1 quarter. The position peaked at $67 in Q1 2024. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 2 Kymera Therapeutics shares in Q2 2024, an estimated $67.
  • Financial Gravity Asset Management first reported a position in Kymera Therapeutics in Q1 2024 and held it in 1 quarter.
  • Financial Gravity Asset Management's Kymera Therapeutics position peaked at $67 in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.